Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.

BMC cancer - 8 May 2018

Molnár Eszter, Rittler Dominika, Baranyi Marcell, Grusch Michael, Berger Walter, Döme Balázs, Tóvári József, Aigner Clemens, Tímár József, Garay Tamás, Hegedűs Balázs

Abstract excerpt

BACKGROUND: Currently, there are no available targeted therapy options for non-V600 BRAF mutated tumors. The aim of this study was to investigate the effects of RAF and MEK concurrent inhibition on tumor growth, migration, signaling and apoptosis induction in preclinical models of non-V600 BRAF mutant tumor cell lines. METHODS: Six BRAF mutated human tumor cell lines CRL5885 (G466 V), WM3629 (D594G), WM3670...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Mitogen-Activated Protein Kinase Kinases

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to raf Kinases

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29739364
DOI: 10.1186/s12885-018-4455-x
PMCID: PMC5941622

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells.PMID 29739364Read ↗

[vestigation of molecular factors determining BRAF-inhibitor sensitivity in solid tumors].Semantic proximity Read ↗

Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.Semantic proximity Read ↗

BRAF as a target for cancer therapy.Semantic proximity Read ↗

BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers.Semantic proximity Read ↗

Combined BRAFV600E and MEK blockade for BRAFV600E-mutant gliomas.Semantic proximity Read ↗

Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Antitumor activity of the ERK inhibitor SCH772984 [corrected] against BRAF mutant, NRAS mutant and wild-type melanoma.Semantic proximity Read ↗

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibSemantic proximity Read ↗

Systemic review on B-RafV600E mutation as potential therapeutic target for the treatment of cancer.Semantic proximity Read ↗

Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK.Semantic proximity Read ↗

BRAF inhibitors in cancer therapy.Semantic proximity Read ↗

Molecular Pathways and Mechanisms of BRAF in Cancer Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.